Myosin Therapeutics Initiates Phase 1/2 STAR-GBM Trial of MT-125 Targeting Non-Muscle Myosin II in Newly Diagnosed Glioblastoma (PR Newswire)
UF startup Myosin Therapeutics has dosed the first patient in its Phase 1/2 glioblastoma trial, advancing the development of a potential new cancer therapy in collaboration with the Mayo Clinic and NCI.
Myosin Therapeutics Awarded Florida Cancer Innovation Fund Grant to Support STAR-GBM Clinical Trial (Myosin News)
UF startup Myosin Therapeutics has been awarded $2 million in funding from the Florida Department of Health through the Casey DeSantis Florida Cancer Innovation Fund to support the company’s STAR-GBM Phase 1/2 clinical trial evaluating MT-125 in patients newly diagnosed with glioblastoma.
Myosin Therapeutics Invited To Present at Biocom California’s Global Partnering & Investor Conference (PR Newswire)
UF startup Myosin Therapeutics has been selected to present at Biocom California’s Global Partnering & Investor Conference. Company leadership will share progress and engage with investors and strategic partners, highlighting continued momentum in advancing its therapeutic pipeline.
Tech Tuesday: University of Florida Lab Showcases How Molecular Motors Can Improve Human Life (WCJB TV20)
In this week’s Tech Tuesday, UF Innovate highlights Myosin Therapeutics, a biomedical company developing myosin inhibitors to treat cancer.
Myosin Therapeutics Receives FDA Fast Track Designation for MT-125 in Glioblastoma (PR Newswire)
UF startup Myosin Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to MT-125 for the treatment of glioblastoma (GBM).
Myosin Therapeutics Awarded $4.5 Million NCI Bridge Grant to Advance Phase I Trial of MT-125 in Glioblastoma (PR Newswire)
UF startup Myosin Therapeutics announced it has been awarded a $4.5M Phase IIB Bridge Award from the National Cancer Institute’s (NCI) Small Business Innovation Research (SBIR) program.
Myosin Therapeutics Receives FDA Clearance To Initiate First-in-Human Trial of MT-125 in Glioblastoma
UF startup Myosin Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Investigational New Drug (IND) application for MT-125.
Myosin Therapeutics Awarded $3 Million NIH Grant To Advance Clinical Trial for MT-110 in Methamphetamine Use Disorder
UF Startup Myosin Therapeutics, Inc., a biotechnology company developing innovative therapies for cancer and neurological disorders, announced that it has been awarded a $3 million grant from NIDA, part of NIH.
Scripps Institute Spin-Out Company Raises $3 Million
UF startup Myosin Therapeutics, a biotechnology company developing medications to treat brain cancer and methamphetamine addiction, secured $3 million in seed funding.
Myosin Therapeutics Closes Second Seed Round To Advance Clinical Trials for Innovative Cancer and Neuroscience Therapies
UF startup Myosin Therapeutics, Inc., a biotechnology company developing novel therapies for cancer and neurological disorders, has closed its second seed funding round, raising over $3 million to supplement significant investment from the National Institutes of Health.